|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP5G2 |
Gene summary for ATP5G2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP5G2 | Gene ID | 517 |
| Gene name | ATP synthase membrane subunit c locus 2 | |
| Gene Alias | ATP5A | |
| Cytomap | 12q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q06055 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 517 | ATP5G2 | GSM4909280 | Human | Breast | Precancer | 3.34e-04 | -6.01e-01 | 0.0305 |
| 517 | ATP5G2 | GSM4909281 | Human | Breast | IDC | 1.63e-27 | -6.01e-01 | 0.21 |
| 517 | ATP5G2 | GSM4909282 | Human | Breast | IDC | 3.98e-27 | -6.01e-01 | -0.0288 |
| 517 | ATP5G2 | GSM4909285 | Human | Breast | IDC | 1.63e-27 | -6.01e-01 | 0.21 |
| 517 | ATP5G2 | GSM4909286 | Human | Breast | IDC | 9.66e-27 | -6.01e-01 | 0.1081 |
| 517 | ATP5G2 | GSM4909287 | Human | Breast | IDC | 5.17e-31 | -6.01e-01 | 0.2057 |
| 517 | ATP5G2 | GSM4909288 | Human | Breast | IDC | 2.46e-08 | -6.01e-01 | 0.0988 |
| 517 | ATP5G2 | GSM4909289 | Human | Breast | IDC | 3.58e-06 | -6.01e-01 | 0.1064 |
| 517 | ATP5G2 | GSM4909290 | Human | Breast | IDC | 1.14e-22 | -6.01e-01 | 0.2096 |
| 517 | ATP5G2 | GSM4909291 | Human | Breast | IDC | 1.18e-18 | -6.01e-01 | 0.1753 |
| 517 | ATP5G2 | GSM4909292 | Human | Breast | IDC | 4.23e-03 | -6.01e-01 | 0.1236 |
| 517 | ATP5G2 | GSM4909293 | Human | Breast | IDC | 9.66e-27 | -6.01e-01 | 0.1581 |
| 517 | ATP5G2 | GSM4909294 | Human | Breast | IDC | 1.63e-27 | -6.01e-01 | 0.2022 |
| 517 | ATP5G2 | GSM4909295 | Human | Breast | IDC | 5.82e-15 | -6.01e-01 | 0.0898 |
| 517 | ATP5G2 | GSM4909296 | Human | Breast | IDC | 9.66e-27 | -6.01e-01 | 0.1524 |
| 517 | ATP5G2 | GSM4909297 | Human | Breast | IDC | 7.38e-30 | -6.01e-01 | 0.1517 |
| 517 | ATP5G2 | GSM4909298 | Human | Breast | IDC | 1.63e-27 | -6.01e-01 | 0.1551 |
| 517 | ATP5G2 | GSM4909299 | Human | Breast | IDC | 9.66e-27 | -6.01e-01 | 0.035 |
| 517 | ATP5G2 | GSM4909300 | Human | Breast | IDC | 2.29e-13 | -6.01e-01 | 0.0334 |
| 517 | ATP5G2 | GSM4909301 | Human | Breast | IDC | 1.11e-28 | -6.01e-01 | 0.1577 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATP5G2 | deletion | Frame_Shift_Del | novel | c.36delN | p.Ser13ProfsTer44 | p.S13Pfs*44 | Q06055 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ATP5G2 | SNV | Missense_Mutation | novel | c.510N>A | p.Phe170Leu | p.F170L | Q06055 | protein_coding | deleterious(0.02) | possibly_damaging(0.793) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| ATP5G2 | SNV | Missense_Mutation | c.533N>T | p.Ala178Val | p.A178V | Q06055 | protein_coding | deleterious(0.04) | benign(0.19) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ATP5G2 | SNV | Missense_Mutation | rs566625928 | c.239N>A | p.Arg80His | p.R80H | Q06055 | protein_coding | deleterious_low_confidence(0.05) | benign(0.01) | TCGA-A5-A0GR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP5G2 | SNV | Missense_Mutation | rs767073937 | c.313N>C | p.Cys105Arg | p.C105R | Q06055 | protein_coding | tolerated_low_confidence(0.67) | benign(0.001) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| ATP5G2 | SNV | Missense_Mutation | rs566625928 | c.239G>A | p.Arg80His | p.R80H | Q06055 | protein_coding | deleterious_low_confidence(0.05) | benign(0.01) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ATP5G2 | SNV | Missense_Mutation | novel | c.337N>G | p.Ser113Gly | p.S113G | Q06055 | protein_coding | deleterious_low_confidence(0.04) | benign(0.084) | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ATP5G2 | SNV | Missense_Mutation | novel | c.463N>T | p.Leu155Phe | p.L155F | Q06055 | protein_coding | deleterious(0.02) | probably_damaging(0.967) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP5G2 | SNV | Missense_Mutation | novel | c.434G>T | p.Gly145Val | p.G145V | Q06055 | protein_coding | deleterious(0.01) | probably_damaging(0.963) | TCGA-73-A9RS-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
| ATP5G2 | SNV | Missense_Mutation | novel | c.76N>T | p.Ala26Ser | p.A26S | Q06055 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.751) | TCGA-21-1075-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |